Suzanne Eldridge
Co-founder and director of ReFleks, a Queen Mary University of London spinout developing a single-injection therapy to repair joint damage and prevent osteoarthritis; Senior Lecturer in Musculoskeletal Regenerative Medicine at QMUL.
1
APPEARANCES
1
PODCASTS
Sep 23, 2026
Zach SuroundsHOST
I wonder if you could just share your views on that and how you guys are thinking about that.
Suzanne EldridgeGUEST
Yeah, so we're, broadly aligning our products with guidelines set by the FDA.
Suzanne EldridgeGUEST
So what we've always strived to achieve with our molecules is to find a disease modifying osteoarthritis drug and the FDA defines that as requiring three parameters.
Suzanne EldridgeGUEST
One of those is pain relief, the other is cartilage regeneration and the final one is limiting abnormal bone formation.
Suzanne EldridgeGUEST
So we might do some initial in vitro screening, and then we take them forward into a humanized mouse model, followed by a mouse model of injury, followed by large animal study that we're doing now with Agrin, which is a sheep study.
12 MINS LATER
Zach SuroundsHOST
I wonder if you could just talk us through... how you think about those two elements living together how you're able to make them both work you know light work life balance like how do you make this all hold together in a reasonable way